Journal of Thrombosis and Thrombolysis

, Volume 31, Issue 4, pp 449–457 | Cite as

Acquired factor V inhibitors: a systematic review

Article

Abstract

The occurrence of an inhibitor against coagulation factor V (FV) is a rare but challenging condition, which may span from asymptomatic laboratory abnormalities to potentially life-threatening bleeding. The onset of FV inhibitors has been associated most frequently in the past with the patients’ exposure to topical bovine thrombin administered during surgery procedures. However, since this preparation is no longer used, in this systematic review we have only focused on non-bovine thrombin-related FV inhibitor cases.

Keywords

FV inhibitors Autoantibodies Bleeding Therapy 

References

  1. 1.
    Knoble P, Lechner K (1998) Acquired factor V inhibitors. Bailliere’s Clin Haematol 11:305–318CrossRefGoogle Scholar
  2. 2.
    Emori Y, Sakugawa M, Niiya K et al (2002) Life-threatening bleeding and acquired factor V deficiency associated with primary systemic amyloidosis. Blood Coagul Fibrinolysis 13:555–559PubMedCrossRefGoogle Scholar
  3. 3.
    Wiwanitkit V (2006) Spectrum of bleeding in acquired factor V inhibitor: a summary of 33 cases. Clin Appl Thromb Hemost 12:485–488PubMedCrossRefGoogle Scholar
  4. 4.
    Morris CJ, Curris N (2009) Acquired factor V inhibitor in a critically ill patient. Anaesthesia 64:1014–1017PubMedCrossRefGoogle Scholar
  5. 5.
    Franchini M, Gandini G, Di Paolantonio T et al (2005) Acquired hemophilia A: a concise review. Am J Hematol 80:55–63PubMedCrossRefGoogle Scholar
  6. 6.
    Franchini M, Targher G, Montagnana M, Lippi G (2008) Laboratory, clinical and therapeutic aspects of acquired hemophilia A. Clin Chim Acta 395:14–18PubMedCrossRefGoogle Scholar
  7. 7.
    Ortel T (1999) Clinical and laboratory manifestations of antifactor V antibodies. J Lab Clin Med 133:326–334PubMedCrossRefGoogle Scholar
  8. 8.
    Favaloro EJ, Bonar R, Duncan E et al (2006) Identification of factor inhibitors by diagnostic haemostasis laboratories: a large multi-centre evaluation. Thromb Haemost 96:73–78Google Scholar
  9. 9.
    Favaloro EJ, Posen J, Ramakrishna R et al (2004) Factor V inhibitors: rare or not so uncommon? A multilaboratory investigation. Blood Coagul Fibrinolysis 15:637–647PubMedCrossRefGoogle Scholar
  10. 10.
    Miesbach W, Voigt J, Peetz D, Scharrer I (2003) Massive bleeding symptoms in two patients with factor V inhibitor and antiphospholipid antibodies after treatment with ciprofloxacin. Med Klin 98:339–343Google Scholar
  11. 11.
    Lucia JF, Aguilar C (2005) A case of an asymptomatic idiopathic inhibitor to coagulation factor V. Haemophilia 11:178–180PubMedCrossRefGoogle Scholar
  12. 12.
    Takahashi H, Fuse I, Abe T, Yoshino N, Aizawa Y (2003) Acquired factor V inhibitor complicated by Hashimoto’s thyroditis, primary biliary cirrhosis and membranous nephropathy. Blood Coagul Fibrinolysis 14:87–93PubMedCrossRefGoogle Scholar
  13. 13.
    Koyama JA, Saito T, Kusano T, Hirosawa S (1995) Factor V inhibitor associated with Sjogren’s syndrome. Br J Haematol 89:893–896PubMedCrossRefGoogle Scholar
  14. 14.
    Streiff MB, Ness PM (2002) Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure. Transfusion 42:18–26PubMedCrossRefGoogle Scholar
  15. 15.
    Banninger H, Hardegger T, Tobler A et al (1993) Fibrin glue in surgery: frequent development of inhibitors of bovine thrombin and human factor V. Br J Haematol 85:528–532PubMedCrossRefGoogle Scholar
  16. 16.
    Ortel TL, Mercer MC, Thames EH, Moore KD, Lawson JH (2001) Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. Ann Surg 233:88–96PubMedCrossRefGoogle Scholar
  17. 17.
    Lu L, Liu Y, Wei J, Zhang L, Yang R (2004) Acquired inhibitor of factor V: first report in China and literature review. Haemophilia 10:661–664PubMedCrossRefGoogle Scholar
  18. 18.
    Leus B, Devreese K, Van den Bossche J, Malfait R (2006) Factor V inhibitor: case report. Blood Coagul Fibrinolysis 17:585–587PubMedCrossRefGoogle Scholar
  19. 19.
    Kajitani M, Ozdemir A, Aguinaga M, Jazieh AR, Flick JT, Antakli T (2000) Hemorrhagic complication due to acquired factor V inhibitor after single exposure to bovine thrombin product. J Card Surg 15:378–382PubMedCrossRefGoogle Scholar
  20. 20.
    Bowman LJ, Anderson CD, Chapman WC (2010) Topical recombinant human thrombin in surgical hemostasis. Semin Thromb Hemost 36:477–484PubMedCrossRefGoogle Scholar
  21. 21.
    Ang AL, Kuperan P, Ng CH, Ng HJ (2009) Acquired factor V inhibitor. A problem-based systematic review. Thromb Haemost 101:852–859PubMedGoogle Scholar
  22. 22.
    Feinstein DI (1978) Acquired inhibitors of factor V. Thromb Haemost 39:663–674PubMedGoogle Scholar
  23. 23.
    Ferguson JH, Johnston CL, Howell DA (1958) A circulating inhibitor (anti-AcG) specific for the labile factor-V of the blood-clotting mechanism. Blood 13:382–397Google Scholar
  24. 24.
    Lopez V, Pflughaupt R, Butler R (1968) A specific inhibitor of human clotting factor V. Acta Haematol 40:275–285PubMedCrossRefGoogle Scholar
  25. 25.
    Hundley DA, Duncan BM (1969) A circulating anticoagulant specific for factor V. Pathology 1:265–272CrossRefGoogle Scholar
  26. 26.
    Feinstein DI, Rapaport SI, McGehee WG, Patch MJ (1970) Factor V anticoagulants: clinical, biochemical and immunological observations. J Clin Invest 49:1578–1588PubMedCrossRefGoogle Scholar
  27. 27.
    Feinstein DI, Rapaport SI, Chong MMY (1973) Factor V inhibitor: report of a case, with comments on a possible effect of streptomycin. Ann Intern Med 78:385–388PubMedGoogle Scholar
  28. 28.
    Onuora CA, Lindenbaum J, Nossel HL (1973) Massive hemorrhage associated with circulating antibodies to factor V. Am J Med Sci 265:407–417PubMedCrossRefGoogle Scholar
  29. 29.
    Nilsson IM, Hedner U, Ekberg M, Denneberg T (1974) A circulating anticoagulant against factor V. Acta Med Scand 195:73–77PubMedCrossRefGoogle Scholar
  30. 30.
    Stenbjerg S, Husted S, Mygind K (1975) A circulating factor V inhibitor: possible side effect of treatment with strepromycin. Scand J Haematol 14:280–285PubMedCrossRefGoogle Scholar
  31. 31.
    Crowell EB (1975) Observations on a factor V inhibitor. Br J Haematol 29:397–404PubMedCrossRefGoogle Scholar
  32. 32.
    Bryning K, Leslie J (1977) Factor V inhibitor and bullous pemphigoid. Br Med J 2:677–678PubMedCrossRefGoogle Scholar
  33. 33.
    Coots MC, Muhleman AF, Glueck HI (1978) Hemorrhagic death associated with a high titer factor V inhibitor. Am J Hematol 4:193–206PubMedCrossRefGoogle Scholar
  34. 34.
    Lane TA, Shapiro SS, Burka ER (1978) Factor V antibody and disseminated intravascular coagulation. Ann Intern Med 89:182–185PubMedGoogle Scholar
  35. 35.
    Lust A, Bellon A (1978) A circulating anticoagulant against factor V. Acta Clin Belg 33:62–65PubMedGoogle Scholar
  36. 36.
    Chediak J, Ashenhurst JB, Garlick I, Desser RK (1980) Sucessful management of bleeding in a patient with factor V inhibitor by platelet transfusion. Blood 56:835–841PubMedGoogle Scholar
  37. 37.
    Abe T, Kazama M, Itokazu K et al (1980) A case of sigmoid cancer who acquired factor V inhibitor producibility and treated with factor VIII bypassing activity preparation FEIBA. Rinsho Ketsueki 21:1664–1673PubMedGoogle Scholar
  38. 38.
    Hida K, Sakamoto S, Takaku F et al (1980) A case of acquired coagulopathy due to factor V inhibitor. Rinsho Ketsueki 21:1589–1596Google Scholar
  39. 39.
    Lerolle D, Dreyer-Dufer C, Allain JP (1981) A circulating inhibitor specific to factor V. Clinical, biological and therapeutic study. Nouv Presse Med 10:1483–1487PubMedGoogle Scholar
  40. 40.
    Kuto M, Izuchi Y, Deguchi K, Morito T, Lee C, Wada H (1981) An inhibitor against factor V occurring postoperatively in a case of pancreatic cancer. Nippon Ketsueki Gakkai Zasshi 44:938–950PubMedGoogle Scholar
  41. 41.
    Vickars LM, Coupland RW, Naiman SC (1985) The response of an acquired factor V inhibitor to activated factor IX concentrate. Transfusion 25:51–53PubMedCrossRefGoogle Scholar
  42. 42.
    Chong LL, Wong YC (1985) A case of factor V inhibitor. Am J Hematol 19:395–399PubMedCrossRefGoogle Scholar
  43. 43.
    Chiu HC, Rao AK, beckett C, Colman RW (1985) Immune complexes containing factor V in a patient with an acquired neutralizing antibody. Blood 65:810–818PubMedGoogle Scholar
  44. 44.
    Nesheim ME, Nichols WL, Cole TL et al (1986) Isolation and study of an acquired inhibitor of human coagulation factor V. J Clin Invest 77:405–415PubMedCrossRefGoogle Scholar
  45. 45.
    Brandt J, Britton A, Kraut E (1986) A spontaneous factor V inhibitor with unexpected laboratory features. Arch Pathol Lab Med 110:224–227PubMedGoogle Scholar
  46. 46.
    Lazarchick J, Wolff M, Pepkowitz SH, Kizer J, Romein LA (1986) Factor V inhibitor associated with immune complex formation. Arch Pathol Lab Med 110:448–451PubMedGoogle Scholar
  47. 47.
    Massignon D, Roullit S, Espinouse D, Coeur P (1989) Occurrence of a circulating anticoagulant, factor V inhibitor after surgical intervention. Ann Fr Anesth Reanim 81:70–72Google Scholar
  48. 48.
    Okajima A, Horii J, Nasu K et al (1989) Factor V inhibitor with double cancer. Rinsho Ketsueki 30:514–519PubMedGoogle Scholar
  49. 49.
    Grigg AP, Dauer R, Thurlow PJ (1989) Bleeding due to an acquired inhibitor of platelet associated factor V. Aust NZ J Med 19:310–314Google Scholar
  50. 50.
    Taillan B, Fuzibet JB, Vinti H et al (1989) Factor V inhibitor in celiac disease. Am J Med 87:360PubMedCrossRefGoogle Scholar
  51. 51.
    Gordon B, haire W, Duggan M, Langnas A (1991) Factor V inhibitor developing after liver transplantation in a 3-year-old child. Pediatrics 88:156–159PubMedGoogle Scholar
  52. 52.
    Buclin T, Schmidt PM, Hauert J, Winkel L, Chapuis G, Bachmann F (1992) Acquired factor V inhibitor treated with intravenous immunoglobulins. Schweiz Med Wochenschr 122:1968–1970PubMedGoogle Scholar
  53. 53.
    Kapur A, Kelsey PR, Isaacs PET (1993) Factor V inhibitor in thrombosis. Am J Hematol 42:384–388PubMedCrossRefGoogle Scholar
  54. 54.
    Smid WM, de Wolf JTM, Nijland JH, Bom VJJ, van der Meer J (1994) Sever bleeding caused by an inhibitor to coagulation factor V: a case report. Blood Coagul Fibrinolysis 5:133–137PubMedCrossRefGoogle Scholar
  55. 55.
    Denis A, Baudeau C, Verdy E, Couderc R, Rondeau E, Sraer JD (1995) Acquired circulating anticoagulant with anti-factor V activity in AIDS: first case report. Nouv Rev Fr Hematol 37:165–169PubMedGoogle Scholar
  56. 56.
    Tribl B, Knobl P, Derfler K et al (1995) Rapid elimination of a high-titer spontanoues factor V antibody by extracorporeal antibody-based immunoadsorption and immunosuppression. Ann Hematol 71:199–203PubMedCrossRefGoogle Scholar
  57. 57.
    George S, Nagabhushana MS, Cyran EM (1995) Coagulopathy due to an acquired factor V inhibitor and subsequently thrombosis. Am J Hematol 49:98–100PubMedCrossRefGoogle Scholar
  58. 58.
    Suehisa E, Toku M, Akita N et al (1995) Study of an antibody against F1F2 fragment of human factor V in a patient with Hashimoto’s disease and bullous pemphigoid. Thromb Res 77:63–68PubMedCrossRefGoogle Scholar
  59. 59.
    Fu YX, Kaufman R, Rudolph AE, Collum SE, Blinder MA (1996) Multimodality therapy of an acquired factor V inhibitor. Am J Hematol 51:315–318PubMedCrossRefGoogle Scholar
  60. 60.
    Brickner LA, Scannell KA, Sahud MA (1996) Acquired factor V inibito in a patient with acquired human immunodeficiency syndrome. Am J Hematol 52:332–333PubMedCrossRefGoogle Scholar
  61. 61.
    Van Spronsen DJ, Oosting JD, Hoffmann JJML, Breed WPM (1998) Factor V inhibitor associated with cold agglutinin disease. Ann Hematol 76:49–50PubMedCrossRefGoogle Scholar
  62. 62.
    Kamphuisen PW, Haan J, Rosekrans PCM, van der Meer FJM (1998) Deep-vein thrombosis and coumarin skin necrosis associated with a factor V inhibitor with lupus-like features. Am J Hematol 57:176–178PubMedCrossRefGoogle Scholar
  63. 63.
    Smith JD, Sindhi R, Rogers R, Lazarchick J (1998) Factor V inhibitor in a liver transplant patient associated with porcine xenoperfusion. Ann Clin Lab Sci 28:280–282PubMedGoogle Scholar
  64. 64.
    Shastri KA, Ho C, Logue G (1999) An acquired factor V inhibitor: clinical and laboratory features. J Med 30:357–366PubMedGoogle Scholar
  65. 65.
    Leroy-Matheron C, Mallat A, Duvoux C et al (1999) Inhibitor against coagulation factor V after liver transplantation. Transplantation 68:1054–1056PubMedCrossRefGoogle Scholar
  66. 66.
    Jansen M, Schmaldienst S, Banyai S et al (2001) Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig-Therasorb). Br J Haematol 112:91–97PubMedCrossRefGoogle Scholar
  67. 67.
    Bayani N, Rugina M, Haddad-Vergnes L, Lelong F (2002) High-titer acquired factor V inhibitor responsive to corticosteroids and cyclophosphamide in a patient with two malignant tumors. Am J Hematol 71:33–36PubMedCrossRefGoogle Scholar
  68. 68.
    Takaku T, Kuriyama Y, Shoji N et al (2002) Simultaneous development of factor V inhibitor and autoimmune thrombocytopenia in a patient with dermatomyositis. Rinsho Ketsueki 43:1050–1054Google Scholar
  69. 69.
    Kalafatis M, Simioni P, Tormene D, Beck DO, Luni S, Girolami A (2002) Isolation and characterization of an antifactor V antibody causino activated protein C resistance from a patient with severe thrombotic manifestations. Blood 99:3985–3992Google Scholar
  70. 70.
    Hasegawa M, Tanaka T, Kii T et al (2003) Acquired inhibitor against coagulation factor V with severe hematuria. Rinsho Ketsueki 44:933–939PubMedGoogle Scholar
  71. 71.
    Okoshi Y, Akiyama H, Inoue T et al (2003) A long-lasting idiopathic factor V inhibitor. Rinsho Ketsueki 44:14–18PubMedGoogle Scholar
  72. 72.
    Ajzner E, Balogh I, Haramura G et al (2003) Anti-factor V auto-antibody in the plasma and platelets of a patient with repeated gastrointestinal bleeding. J Thromb Haemost 1:943–999PubMedCrossRefGoogle Scholar
  73. 73.
    de Raucourt E, Barbier C, Sinda P, Dib M, Peltier JY, Ternisien C (2003) High-dose intravenous immunoglobulin treatment in two patients with acquired factor V inhibitors. Am J Hematol 74:187–190PubMedCrossRefGoogle Scholar
  74. 74.
    Lian EC, Tzakis AG, Andrews D (2004) Response of factor V inhibitor to rituximab in a patient who received liver transplantation for primary biliary cirrhosis. Am J Hematol 77:363–365PubMedCrossRefGoogle Scholar
  75. 75.
    Tukić L, Stamatović D, Tarabar O, Elez M, Zorić M, Mandić-Radić S (2005) Acquired factor V inhibitors in a polytraumatized patient. Vojnosanit Pregl 62:587–590PubMedCrossRefGoogle Scholar
  76. 76.
    Godart B, Boinot C, Remblier C, Hajjar A, Beauchant M (2006) Acquired factor V inhibitor associated with valproic acid use in a cirrhotic patient. Gut 55:134–135PubMedCrossRefGoogle Scholar
  77. 77.
    Perdekamp MT, Rubenstein DA, Jesty J, Hultin MB (2006) Platelet factor V supports hemostasis in a patient with an acquired factor V inhibitor, as shown by prothrombinase and tenase assys. Blood Coagul Fibrinolysis 17:593–597PubMedCrossRefGoogle Scholar
  78. 78.
    Gacina P, Kusec R, Carzavec D, Raic B, Stancic V (2006) Acquired factor V inhibitor: a case report. Acta Clin Croat 45:199–201Google Scholar
  79. 79.
    Endo H, Kawauchi K, Tomimatsu M et al. (2007) Acquired factor V inhibitor responsive to corticosteroids in a patient with double cancers. Intern Med 46:621–625Google Scholar
  80. 80.
    Maughan EO, Wilson J, Wilde JT (2007) Spontaneous resolution of acquired factor V inhibitor associated with ovarian carcinoma. Int J Lab Hematol 29:316–319PubMedCrossRefGoogle Scholar
  81. 81.
    Milojkovic D, Patel R, Ford E, Arya R, Mufti G (2007) Acquired factor V inhibitor after hematopoietic stem cell transplantation. Thromb Haemost 98:685–687PubMedGoogle Scholar
  82. 82.
    Shimizu I, Ichikawa N, Yotsumoto M, Sumi M, Ueno M, Kobayashi H (2008) High-titer idiopathic acquired factor V inhibitor patient showing decreased activities of multiple coagulation factors. Rinsho Ketsueki 49:413–416PubMedGoogle Scholar
  83. 83.
    Jeimy SB, Krakow EF, Fuller N, Tasneem S, Hayward CPM (2008) An acquired factor V inhibitor associated with defective factor V function, storage and binding to multimerin 1. J Thromb Haemost 6:395–397PubMedGoogle Scholar
  84. 84.
    Lebrun A, Leroy-Matheron C, Arlet JB, Bartolucci P, Michel M (2008) Successful treatment with rituximab in a patient with an acquired factor V inhibitor. Am J Hematol 83:163–164PubMedCrossRefGoogle Scholar
  85. 85.
    William BM (2008) Adjunctive role for recombinant activated factor VII in the treatment of bleeding secondary to a factor V inhibitor. Blood Coagul Fibrinolysis 19:327–328PubMedCrossRefGoogle Scholar
  86. 86.
    Gadelha T, Aquino JHW, Silva EA, Santos FL, de Oliveira MHFC (2008) The diversity in clinical presentation of acquired factor V inhibitor, two case reports. Acta Haematol 119:108–110PubMedCrossRefGoogle Scholar
  87. 87.
    Kindler S, Siegemund T, Fuhrer D, Petros S (2008) Thrombin generation assay in a patient with acquired factor V inhibitor. J Thromb Haemost 6:1985–1987PubMedCrossRefGoogle Scholar
  88. 88.
    Shanmugam H, Jayaranee S, Eow GI (2010) A case report of an acquired inhibitor to coagulation factor V. Haemophilia [Epub ahead of print]Google Scholar
  89. 89.
    Tessier-Marteau A, Croquefer S, Meziani F, Cau S, Asfar P, Macchi L (2010) Acquired factor V inhibitor in a context of sepsis and disseminated intravascular coagulation. Am J Hematol 85:145–146PubMedGoogle Scholar
  90. 90.
    Franchini M, Lippi G (2010) Recombinant activated factor VII: mechanisms of action and current indications. Semin Thromb Haemost 36:485–492CrossRefGoogle Scholar
  91. 91.
    Yu Z, Lennon VA (1999) Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 340:227–228PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Servizio di Immunoematologia e Medicina Trasfusionale, Dipartimento di Patologia e Medicina di LaboratorioAzienda Ospedaliero-Universitaria di ParmaParmaItaly
  2. 2.U.O di Diagnostica Ematochimica, Dipartimento di Patologia e Medicina di LaboratorioAzienda Ospedaliero-Universitaria di ParmaParmaItaly

Personalised recommendations